AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...

AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

AngioDynamics, Inc. ( NASDAQ: ANGO) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET James C. Clemmer - CEO, President & Director Stephen A. Trowbridge - Executive VP & CFO ...

AngioDynamics expects full-year results to range from a loss of 35 cents per share to a loss of 25 cents per share, with revenue in the range of $305 million to $310 million. AngioDynamics shares have ...

Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

AngioDynamics Inc (ANGO) reports a robust 12% revenue increase, driven by Med Tech advancements, despite facing tariff ...